Leavitt Plans India Visit To Discuss Safe Pharmaceutical Exports (India)
This article was originally published in PharmAsia News
The head of the U.S. Department of Health and Human Services plans a January visit to India to discuss ways to make medicines and medical products safe for the U.S. market. During his visit, Secretary Mike Leavitt plans to visit sites that make drugs, food and other products intended for export to the United States. One of Leavitt's visits is to be made to a facility delivering polio vaccine, but his schedule also includes visits with business people and senior officials in the Indian government. (Click here for more
You may also be interested in...
Purdue’s opioid settlement is making headlines for the size of the financial penalty. But the plan to re-imagine Purdue as a ‘public benefit company’ could have far-reaching significance for the industry – if it ever gets off the ground.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Given concerns about completing Phase III trials, advisory committee member asks whether US FDA has considered ‘the possibility of an expanded access protocol,’ but agency official points to added complexity that comes with the pathway; bioethics experts talk to the Pink Sheet about pros and cons of expanded access vs. EUA pathways.